Fibrosarkoma

01Pathophysiology

Fibrosarcoma arises from the malignant transformation of fibroblasts, the cells responsible for producing collagen and maintaining the extracellular connective tissue matrix. Unlike other sarcomas that differentiate toward bone (osteosarcoma) or cartilage (chondrosarcoma), fibrosarcoma produces only collagen, without any other mesenchymal elements. This distinction is what defines the tumor histologically and separates it from other spindle cell neoplasms.

The malignant fibroblasts proliferate in an uncontrolled fashion and arrange themselves into interlacing fascicles that, when cut in cross-section, produce the characteristic herringbone pattern on microscopy. This architectural pattern reflects the way tumor cells align in sweeping bundles that intersect at acute angles. Understanding this pattern is essential, as it is the single most tested histologic feature of fibrosarcoma on board examinations.

In adult-type fibrosarcoma, the tumor typically arises de novo in the deep soft tissues of the extremities, particularly the thigh, and grows as a painless, progressively enlarging mass. Because the tumor is deep-seated and initially painless, patients often present late with tumors already exceeding 5 cm. The tumor invades locally along fascial planes and has a propensity for hematogenous metastasis to the lungs, which is why chest imaging is part of the staging workup.

In infantile (congenital) fibrosarcoma, the molecular driver is a characteristic t(12;15)(p13;q25) translocation that generates the ETV6-NTRK3 fusion oncogene. This fusion constitutively activates a tyrosine kinase signaling pathway (the NTRK pathway), driving uncontrolled cell proliferation. Despite being histologically similar to the adult form, the infantile variant carries a significantly better prognosis and responds remarkably well to chemotherapy. The identification of the NTRK fusion has also opened the door to targeted therapy with NTRK inhibitors such as larotrectinib and entrectinib.

Secondary fibrosarcoma of bone can develop in the setting of pre-existing bone pathology, including Paget disease, bone infarcts, fibrous dysplasia, or prior radiation exposure. These cases represent malignant transformation of the fibrous stroma within the affected bone. On imaging, bone fibrosarcoma produces a purely lytic lesion because the malignant fibroblasts produce only collagen (not osteoid), meaning there is no mineralized matrix visible on X-ray. This absence of matrix production is a distinguishing radiographic feature that separates fibrosarcoma from osteosarcoma (which produces osteoid matrix, seen as a "sunburst" pattern or Codman triangle).

02Classification and Clinical Manifestation

Histologic Grading (FNCLCC System):

The FNCLCC (French Federation of Cancer Centers) grading system is the standard method for grading soft tissue sarcomas and directly influences treatment decisions and prognosis. Higher grades correlate with greater metastatic potential and poorer outcomes.

03Diagnostic Workup

The diagnostic approach to fibrosarcoma begins with imaging and is confirmed by tissue biopsy. For any patient presenting with a deep soft tissue mass, particularly one that is larger than 5 cm, deep to the fascia, or progressively enlarging, MRI with gadolinium contrast is the best initial imaging study. MRI provides superior soft tissue resolution and delineates the relationship of the tumor to surrounding neurovascular bundles, which is critical for surgical planning. The tumor typically appears as a heterogeneous mass with intermediate to low signal intensity on T1 and high signal on T2-weighted sequences, often with internal areas of necrosis and hemorrhage.

For bone lesions, a plain radiograph is the best initial test. Fibrosarcoma of bone produces a purely lytic, destructive lesion with no evidence of matrix mineralization. This is a high-yield discriminator: the absence of calcified matrix (no osteoid, no chondroid) distinguishes fibrosarcoma from osteosarcoma and chondrosarcoma.

After imaging suggests a soft tissue or bone sarcoma, the next step is tissue diagnosis via biopsy. A core needle biopsy is generally preferred over fine needle aspiration because it preserves tissue architecture, which is essential for identifying the herringbone pattern. Incisional biopsy is reserved for cases where core biopsy is non-diagnostic. The biopsy must be performed carefully along the planned surgical approach to avoid contaminating additional tissue planes.

On histopathology, the hallmark finding is a herringbone pattern consisting of interlacing fascicles of uniform, elongated spindle cells with tapered nuclei. The cells produce collagen, and reticulin stain highlights individual tumor cells surrounded by reticulin fibers (in contrast to fibrous histiocytoma where reticulin wraps around cell clusters).

Immunohistochemistry is used primarily to exclude other spindle cell neoplasms. Fibrosarcoma is characteristically vimentin positive (as are most mesenchymal tumors) but negative for all other lineage markers: S-100 (neural/melanocytic), desmin and smooth muscle actin (muscle), cytokeratin (epithelial), and CD34 (vascular/DFSP). This "vimentin-only" profile is a useful test-taking shortcut.

In suspected infantile fibrosarcoma, molecular testing by FISH or RT-PCR to detect the ETV6-NTRK3 fusion is essential, as this confirms the diagnosis and identifies candidates for NTRK-targeted therapy.

Staging is completed with CT of the chest to evaluate for pulmonary metastases, which represent the most common site of distant spread via hematogenous dissemination.

04Management and Treatment

The cornerstone of treatment for fibrosarcoma is wide surgical excision with the goal of achieving negative histologic margins (R0 resection). The minimum recommended margin is 1 to 2 cm of grossly normal tissue surrounding the tumor, including a cuff of uninvolved fascia or muscle. Limb-sparing surgery is preferred whenever oncologically feasible, and amputation is reserved only for cases where adequate margins cannot be achieved without sacrificing limb function.

Adjuvant radiation therapy is recommended for all high-grade fibrosarcomas and for cases where surgical margins are positive or close (less than 1 cm). Preoperative (neoadjuvant) radiation is typically delivered at a dose of 50 Gy in 25 fractions and has the advantage of treating a smaller field with less tissue edema. Postoperative radiation is delivered at a higher dose of 60 to 66 Gy in 30 to 33 fractions to compensate for the larger surgical bed and absence of intact tissue planes. The choice between preoperative and postoperative radiation depends on institutional preference and tumor characteristics, but the key exam point is that radiation is added to surgery, not used as a standalone treatment.

For metastatic fibrosarcoma, systemic chemotherapy with doxorubicin is the first-line treatment. Single-agent doxorubicin at 75 mg/m² IV every 21 days remains the standard. For patients who need a higher response rate (e.g., to achieve tumor shrinkage for potential surgical resection), the combination of doxorubicin plus ifosfamide (AIM regimen) can be used, though at the cost of increased toxicity, including myelosuppression and ifosfamide-induced hemorrhagic cystitis (prevented with mesna). The cumulative lifetime dose of doxorubicin must be monitored carefully, with a maximum of 450 to 550 mg/m² to avoid dose-limiting cardiotoxicity (dilated cardiomyopathy). Baseline and serial echocardiography or MUGA scans are required.

Infantile fibrosarcoma deserves special mention because its management differs significantly. If the tumor can be completely excised without functional impairment, surgery alone may be curative. However, because many infantile tumors are large and located on the distal extremities, upfront surgery would often require amputation. In such cases, neoadjuvant chemotherapy is used first to shrink the tumor and enable limb-sparing surgery. The standard regimen is vincristine plus actinomycin D, borrowed from protocols used for pediatric soft tissue sarcomas. Response rates are excellent, with most tumors showing dramatic reduction in size.

The identification of the NTRK fusion in infantile fibrosarcoma has introduced a paradigm-shifting targeted therapy option. Larotrectinib and entrectinib are FDA-approved NTRK inhibitors that produce high response rates in NTRK fusion-positive tumors across all tumor types (tumor-agnostic indication). This is a high-yield concept: NTRK inhibitors are approved based on the molecular alteration, not the tissue of origin. Larotrectinib is dosed at 100 mg PO twice daily in adults and 100 mg/m² PO twice daily in pediatric patients.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students get fibrosarcoma questions wrong is by confusing it with other spindle cell tumors, particularly undifferentiated pleomorphic sarcoma and synovial sarcoma. The exam relies on histologic pattern recognition and immunohistochemistry panels to test whether you can differentiate between these. The single most important pearl is the herringbone pattern: if you see interlacing fascicles of uniform spindle cells on pathology and the IHC panel is "vimentin-only positive" (everything else negative), the answer is fibrosarcoma.

A second trap involves fibrosarcoma of bone. Students often select osteosarcoma or chondrosarcoma when shown a destructive bone lesion. The discriminator is the absence of matrix production: fibrosarcoma produces a purely lytic lesion, while osteosarcoma produces osteoid (visible as sclerotic or mixed density) and chondrosarcoma produces chondroid matrix ("rings and arcs" calcification). If a bone lesion is purely lytic with no matrix and the biopsy shows a herringbone pattern, you are looking at fibrosarcoma, not osteosarcoma.

A third common error involves the infantile type. Students may treat infantile fibrosarcoma with the same aggressive approach as adult soft tissue sarcomas, but the prognosis and management differ dramatically. Infantile fibrosarcoma has an excellent prognosis (greater than 90% survival), responds well to chemotherapy, and now has a targeted therapy option with NTRK inhibitors. The exam may test your knowledge of the ETV6-NTRK3 fusion and whether you would order molecular testing in a newborn or infant with a rapidly growing extremity mass.

Finally, be aware that the exam may present a vignette of a patient with a known history of Paget disease or prior radiation therapy who develops new pain or a new lytic lesion. The "next best step" in such a scenario is imaging followed by biopsy. The diagnosis is secondary fibrosarcoma (or another secondary sarcoma), and the tested concept is recognizing malignant transformation in the setting of chronic bone pathology or radiation exposure. The core competency here is connecting the clinical context (prior radiation, Paget disease) with the new destructive lesion to arrive at the correct diagnosis of secondary sarcoma rather than dismissing the symptoms as progression of the underlying benign condition.